KALA News and Press, Kala Pharmaceuticals Inc. From 01/07/21

-- First and only prescription therapy approved specifically for short-term treatment of the signs and symptoms of dry eye disease now available in pharmacies nationwide -- -- Advancing multiple NCE development programs targeted to address front and back of eye diseases ...

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will participate in two investor conferences in January. Mark Iwicki, Chairman a...

Kala Pharmaceuticals got its second ocular therapy, Eysuvis, approved on October 27. Peak sales estimates range from $500 million to over $1 billion due to its unique targeting of acute, episodic dry eye that is more common rather than the chronic version. Despite this progress, K...

Today, we revisit Kala Pharmaceuticals for the first time since spring. The company recently garnered an important FDA approval and is executing well despite some continuing COVID-19 challenges. A fully updated investment analysis is presented in the paragraphs below. For fu...

-- Poster presentation and promotional activities highlighted at the American Academy of Ophthalmology 2020 Virtual Annual Meeting -- -- On-track to begin shipping EYSUVIS to wholesalers in mid-December -- -- Wholesale Acquisition Cost announced -- Kala Pharmaceu...

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will present at the Jefferies 2020 Virtual London Healthcare Conference. Mark Iwicki...

Kala Pharmaceuticals, Inc. (KALA) Q3 2020 Earnings Conference Call November 05, 2020, 08:00 AM ET Company Participants Niranjan Kameswaran - SVP, Strategy Mary Reumuth - CFO Mark Iwicki - Chairman, President and CEO Kim Brazzell - Chief Medical Officer Todd Bazemore - COO Hongming Chen - Chie...

Kala Pharmaceuticals (KALA): Q3 GAAP EPS of -$0.50 misses by $0.06.Revenue of $2.22M (+53.1% Y/Y) beats by $0.21M.Shares +2.07% PM.Press Release For further details see: Kala Pharmaceuticals EPS misses by $0.06, beats on revenue

-- Obtained FDA Approval for EYSUVIS TM , First Prescription Therapy Approved Specifically for the Short-Term Treatment of the Signs and Symptoms of Dry Eye Disease -- -- EYSUVIS Expected to Begin Shipping to Wholesalers by End of 2020 -- -- 3Q 2020 INVELTYS® Net Reve...

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will report third quarter 2020 financial results on Thursday, November 5, 2020. Mana...